Healthcare / BiotechnologyNasdaqGM
$3.02
-0.05 (-1.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-211.4M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$330M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-80.5%
↓Gross Margin
N/A
•Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-223.1M · FCF $-190.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Net Income | $-223.1M | $-223.1M | $-258.7M | $-245.6M | $-221.9M | $-169.1M | $-139.7M | $-77.3M | $-74.5M | $-19.6M | $-7.6M | $-68.0M | $-9.5M |
| EBITDA | $-210.2M | $-210.2M | $-247.5M | $-236.6M | $-213.7M | $-164.0M | $-133.2M | $-75.7M | $-70.8M | — | — | — | — |
| EPS | -2.01 | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | -1.58 | — | — | — | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.06 | 0.05 | 0.05 | — | — | — | — | — | — | — | — |
| Current Ratio | 6.12 | 6.12 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-190.5M | $-190.5M | $-215.6M | $-211.4M | $-186.8M | $-128.8M | $-95.2M | $-87.9M | $-55.2M | $-16.7M | $-5.8M | — | — |
| Returns | |||||||||||||
| ROE | -80.5% | -80.5% | -55.9% | -49.9% | -45.3% | -37.2% | -27.7% | -25.1% | -38.4% | -126.2% | -90.5% | -437.5% | 18.5% |
| Valuation | |||||||||||||
| P/B | 1.21 | 1.21 | 2.57 | 4.82 | 2.71 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| EPS Growth | 26.4% | 26.4% | 6.5% | 10.4% | — | -6.0% | -59.5% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.73 → -2.01
Residual
+20.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.